Literature DB >> 19751875

Neoplastic transformation after radiosurgery or radiotherapy: risk and realities.

Ajay Niranjan1, Douglas Kondziolka, L Dade Lunsford.   

Abstract

In recent years, the use of radiosurgery or radiotherapy for benign brain tumors has increased significantly. Although long-term follow-up from several centers suggests that radiosurgery or radiotherapy is effective and safe, there are particular concerns regarding development of radiation-induced tumors. This article reviews the use of radiosurgery and fractionated radiation therapy with particular regard to new tumor induction and malignant transformation. The authors have found that the risk of radiation associated tumors after radiosurgery or radiotherapy for benign brain tumors is very low. All patients should be informed about the risks and consequences of radiation and microsurgery. The current practice standards for radiosurgery should not be modified because of this very low risk.

Entities:  

Mesh:

Year:  2009        PMID: 19751875     DOI: 10.1016/j.otc.2009.04.005

Source DB:  PubMed          Journal:  Otolaryngol Clin North Am        ISSN: 0030-6665            Impact factor:   3.346


  9 in total

Review 1.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

Review 2.  Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review.

Authors:  Leland Rogers; Igor Barani; Marc Chamberlain; Thomas J Kaley; Michael McDermott; Jeffrey Raizer; David Schiff; Damien C Weber; Patrick Y Wen; Michael A Vogelbaum
Journal:  J Neurosurg       Date:  2015-01       Impact factor: 5.115

Review 3.  Radiotherapy for benign disease; assessing the risk of radiation-induced cancer following exposure to intermediate dose radiation.

Authors:  Stephanie R McKeown; Paul Hatfield; Robin J D Prestwich; Richard E Shaffer; Roger E Taylor
Journal:  Br J Radiol       Date:  2015-10-14       Impact factor: 3.039

4.  Secondary malignancy following stereotactic radiosurgery for benign neurologic disease: A cohort study and review of the literature.

Authors:  Alexander D Sherry; Brian Bingham; Ellen Kim; Meredith Monsour; Guozhen Luo; Albert Attia; Lola B Chambless; Anthony J Cmelak
Journal:  J Radiosurg SBRT       Date:  2020

5.  MIB-1 labeling index predicts recurrence in intraventricular central neurocytomas.

Authors:  Gurvinder Kaur; Ari J Kane; Michael E Sughrue; Michael Oh; Michael Safaee; Matthew Sun; Terik Tihan; Michael W McDermott; Mitchel S Berger; Andrew T Parsa
Journal:  J Clin Neurosci       Date:  2012-11-05       Impact factor: 1.961

6.  What intervention is best practice for vestibular schwannomas? A systematic review of controlled studies.

Authors:  John G Wolbers; Alof Hg Dallenga; Alejandra Mendez Romero; Anne van Linge
Journal:  BMJ Open       Date:  2013-02-22       Impact factor: 2.692

Review 7.  Radiation-induced meningiomas in multiple regions, showing rapid recurrence and a high MIB 1 labeling index: a case report and review of the literature.

Authors:  Yoshiaki Goto; So Yamada; Shoko M Yamada; Hiroshi Nakaguchi; Katsumi Hoya; Mineko Murakami; Kazuto Yamazaki; Yasuo Ishida; Akira Matsuno
Journal:  World J Surg Oncol       Date:  2014-04-26       Impact factor: 2.754

8.  Stereotactic Radiosurgery (SRS) Induced Higher-Grade Transformation of a Benign Meningioma into Atypical Meningioma.

Authors:  Ali Basalamah; Mohammed Al-Bolbol; Osman Ahmed; Nagoud Ali; Sabah Al-Rashed
Journal:  Case Rep Surg       Date:  2022-02-23

9.  Risk of secondary malignant neoplasms in children following proton therapy vs. photon therapy for primary CNS tumors: A systematic review and meta-analysis.

Authors:  Rituraj Upadhyay; Divya Yadav; Bhanu P Venkatesulu; Raj Singh; Sujith Baliga; Raju R Raval; Margot A Lazow; Ralph Salloum; Maryam Fouladi; Elaine R Mardis; Nicholas G Zaorsky; Daniel M Trifiletti; Arnold C Paulino; Joshua D Palmer
Journal:  Front Oncol       Date:  2022-08-12       Impact factor: 5.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.